Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Chlorthalidone with Losartan: Patients to receive Chlorthalidone + Losartan 12.5/50 mg/day, can be escalated to 25/100 mg/day once daily at night for 8 weeks
Control Intervention1: Amlo
Sponsors
BMCRI
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patient willing to give written informed consent 2.Patients who are diagnosed to be having Stage 2 hypertension as per JNC 8 guidelines
Exclusion criteria
Exclusion criteria: 1.Patients having comorbidities like Chronic kidney disease, Stroke , Congestive Heart Failure, Myocardial infarction , Coronary Artery Disease, Psychiatric Disorders, Suspected Secondary Hypertension (Eg. Renal artery stenosis, Cushingââ?¬•s syndrome ) 2.Pregnant and Lactating mothers 3.Patients with hypersensitivity to the study medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean reduction in systolic/diastolic blood pressure after 8 weeks of therapyTimepoint: Baseline , 4 weeks and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients achieving Target Blood pressure of ââ?°Â¤ 140/90 mmHg Timepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactMamatha K
Bangalore Medical College and Research Institute
Outcome results
None listed